Curcumin: Nature's Most Powerful Anti-Cancer Compound

Why this ancient spice targets cancer metabolism, cancer stem cells, inflammation, and the tumor microenvironment.

Curcumin, popularly called “curry powder” or turmeric, is a polyphenol extracted from Curcuma longa. Curcumin has antioxidant, anti-inflammatory, antimicrobial, antiviral, and anticancer properties. (1) Curcumin has potent anticancer effects, being the most potent inhibitor of the Warburg glycolytic enzymes, has strong activity against cancer stem cells and strongly influences the tumor microenvironment. Curcumin modulates the activity of more enzymes, regulatory factors and proteins than any other anti-cancer agent (see Figure 1). Curcumin should therefore be prescribed to every cancer patient (unless a contraindication exists).

Anticancer pathways and mechanisms

Curcumin has been shown to interfere with multiple cell signaling pathways in cancer cells, including (see figure 1): (2-19)

i. Cell cycle (cyclin D1 and cyclin E)

ii. Apoptosis (activation of caspases and down-regulation of antiapoptotic gene products), proliferation (HER-2, EGFR, and AP-1)

iii. Survival (PI3K/AKT pathway)

iv. Invasion (MMP-9 and adhesion molecules)

v. Angiogenesis (VEGF)

vi. Metastasis (CXCR-4)

vii. Inflammation (NF-kappa B, TNF, IL-6, IL-1, COX-2, and 5-LOX)

Aberrant activation of NF-κB is characteristic of cancer, with NF-κB playing a major role in cancer angiogenesis, proliferation, metastasis, inflammation, and through the induction of cell survival pathways and inhibition of apoptosis. Phosphorylated NF-ΚB binds DNA and starts the transcription of oncogenes that block apoptosis and initiates cellular proliferation and angiogenesis. (1) Curcumin suppresses NF-ΚB activity by inhibiting the phosphorylation by I kappa B kinase and impeding nuclear translocation of the NF-ΚB p65 subunit. STAT3, is a common target for several signaling pathways regulating oncogenes, as well as modulating the transduction of pro-inflammatory cytokines and growth factors. (1) STAT3 contributes to the growth and survival of the cancer cell, increasing the expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL, thereby blocking apoptosis. Several factors, such as IL-6, as well as EGFR and PDGF, are reported to be STAT3 activators. (20) STAT3 is reported to be a molecular target of curcumin in several tumors, both directly and indirectly by inhibition of IL-6. (21) The accumulation and activation of immune suppressive cells like Treg, Th17, and MDSCs, the differentiation of macrophages toward the M2 phenotype, and the absence of functional DCs are all caused by STAT3 activation. Curcumin significantly decreases STAT3 phosphorylation. (10) Curcumin inhibits breast cancer cell lines through inhibiting HER2-tyrosine kinase. (22) Curcumin inhibits the phosphorylation of Akt, mTOR, and their downstream proteins, resulting in cell cycle arrest in various breast cancer cell lines. (23)

Curcumin downregulates hexokinase-2 and dissociates HK-2 from the mitochondria inducing apoptosis. (24) Curcumin is also able to interfere with the cell signaling pathway of EGFR, a family of receptor tyrosine kinases, that is reported to be associated with the proliferation, adhesion, migration, and differentiation of cancer cells. (25, 26) Curcumin inhibited the growth and proliferation of breast cancer cells by reducing EGFR signaling and decreasing EGFR and Akt levels. (25) Curcumin has been demonstrated to induce apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. (26) In pancreatic cancer cells, curcumin potentiates the anticancer activity of gemcitabine via inhibition of NF-κB, proliferation, angiogenesis, and expression of Cdc20, which is associated with enhanced cell proliferation and invasion. (27)

Curcumin has an impact on the tumor microenvironment by inhibiting angiogenesis even under the hypoxic status within the tumor microenvironment. (7) Furthermore, curcumin has activity against cancer stem cells in addition to promoting apoptosis. (7, 11, 18, 28) Curcumin induces apoptosis in tumor cells, (2) through ROS-mediated endoplasmic reticulum (ER) stress and mitochondrion-dependent pathways. (7) In addition, curcumin acts through the Wnt/-catenin pathway. (9, 19)

Clinical studies

Despite the broad anticancer activities of curcumin in experimental models, its clinical use has been limited by its poor bioavailability. Its oral bioavailability is low due to its poor absorption, extensive phase I and II biotransformation, and rapid elimination through the gall bladder. (29) Due to its low solubility in water and poor absorption, it is traditionally taken with full-fat milk and black pepper, which enhance its absorption. To improve the bioavailability, various curcumin analogs and novel drug delivery systems (e.g., phospholipids, lecithinized curcumin, nanoparticles, and liposomes) are under investigation.

While a few case series describing the use of curcumin in cancer have been published, (3, 16, 30-34) the clinical efficacy of curcumin has been evaluated in a limited number of studies. In a pilot randomized clinical trial in patients with multiple myeloma, the addition of curcumin (4 g twice daily for 28 days) to treatment with melphalan and prednisone increased the rates of remission ([75% vs. 33.3%, p=0.009]. (5) In this study NF-ΚB, VEGF, and TNF levels were significantly lower in the curcumin group with TNF levels being strongly correlated with remission [OR=1.35; 95% CI=1.03-1.76, p=0.03]. In a phase IIa, open-labeled trial patients with metastatic colorectal cancer were randomized to fluorouracil/oxaliplatin chemotherapy (FOLFOX) compared with FOLFOX + 2 g oral curcumin/d (CUFOX). (35) In the intention-to-treat population, the HR for overall survival was 0.34 (95% CI: 0.14, 0.82; P = 0.02) (median of 200 and 502 days for FOLFOX and CUFOX, respectively). In a prospective, single-arm phase II study, Pastorelli et al evaluated the use of a phytosome complex of curcumin (2 g/day) as adjunctive therapy with gemcitabine in patients with advanced pancreatic cancer. (36) The median overall survival of patients treated with gemcitabine as a single agent is 5.7 months. (37) These investigators reported a 27.3% of response rate with 34.1% of cases having stable disease, with a total disease control rate of 61.4%. The median progression-free survival and overall survival were 8.4 and 10.2 months, respectively. Saghatelyan et al randomized 150 women with advanced metastatic breast cancer to receive either paclitaxel plus placebo or paclitaxel plus curcumin once per week for 12 weeks with 3 months of follow-up. (38) In this study, the curcumin was given intravenously. The intention-to-treat analysis revealed that the objective response rate of curcumin was significantly higher than that of the placebo (51% vs. 33%, p<0.01) at 4 weeks of follow-up. The difference between the groups was even greater when only patients who had completed the treatment (61% vs. 38%, odds ratio =2.64, p<0.01) were included.

In dose escalation studies, up to 10 g of curcumin taken daily has been shown to be well tolerated. Patients with breast cancer taking 6 g/day of curcumin for 7 weeks, and patients with prostate cancer who took 3 g/day of curcumin for 9 weeks exhibited no adverse effects. [301,353,389]

Figure 1. A multifaceted anti-cancer agent

Types of cancers that curcumin (turmeric) may be beneficial for

Colorectal, lung, pancreatic, breast, prostate, chronic myeloid leukemia, liver, gastric, brain tumors, ovarian, skin, head and neck, lymphoma, esophageal cancer, and myeloma. (1, 19)

Drug formulations and cautions

Curcumin has been characterized as “generally safe” by the US Food and Drug Administration (FDA). (39) No toxicity is seen for doses of up to 8–10 g/day. (16, 17, 19, 33, 40, 41) However, diarrhea can be a frequent side effect, especially if the daily dose exceeds 4 g. (16) Hepatic injury (hepatitis) is a rare complication and therefore liver function tests should be monitored during long-term use. (42)

Major contraindications

• Gallbladder or bile duct disease
  Curcumin can stimulate bile production and gallbladder contraction, which may worsen gallstones, bile duct obstruction, or biliary colic; people with these conditions are usually advised to avoid concentrated turmeric/curcumin supplements unless cleared by a clinician.​

• Bleeding risk and surgery
  Curcumin has mild anticoagulant/antiplatelet effects and can potentiate blood thinners, increasing bleeding risk; many sources recommend stopping turmeric/curcumin supplements at least 2 weeks before planned surgery and using caution in anyone with a bleeding disorder or on anticoagulant or antiplatelet drugs.​

• Liver disease or prior liver injury from turmeric/curcumin
  Although most people tolerate it, there are documented cases of turmeric/curcumin‑associated drug‑induced liver injury; regulators and liver experts advise avoiding turmeric/curcumin supplements in people with current or past significant liver problems and discontinuing immediately if jaundice or other liver symptoms occur.

Curcumin’s native oral bioavailability is extremely low, so multiple “generations” of formulations now exist that improve solubility, stability, and absorption by up to several hundred‑fold in pharmacokinetic studies. These strategies differ in how they alter curcumin’s chemical environment (lipids, polymers, cyclodextrins, spices, etc.) and in whether they increase total conjugated curcinoids, free curcumin, or both (see table 1). (43)

The manipulation and encapsulation of curcumin into a nanocarrier formulation can overcome the major bioavailability drawbacks and may lead to a far superior therapeutic efficacy. In a murine Hodgkin’s Lymphoma model, formulating curcumin in solid lipid nanoparticles exhibited greater anticancer activity compared to curcumin alone. (44)

Curcumin–galactomannan complexes (CGM; e.g., CurQfen‑type). Fenugreek‑derived soluble fibers encapsulate curcumin, enhancing both bioavailability of free curcuminoids and mucosal interaction.​ Human data report ~12–40‑fold higher free curcuminoid bioavailability and improved antioxidant markers at relatively low doses (e.g., 400–500 mg/day).(45)

Phytosome complex curcumin to phospholipids (usually phosphatidylcholine), creating amphiphilic particles that integrate well into cell membranes and lipoproteins.​ Phytosomal curcumin (Merivia-type):

• Rat and human data show ~5–20‑fold higher plasma levels than unformulated curcumin at equivalent doses.​

• Clinical data supports improved tissue delivery and efficacy at relatively modest daily doses, with good safety

A 2018 pharmacokinetic review (11 formulations) found NovaSol‑type micelles (~185‑fold), CurcuWin‑type (~136‑fold), and LongVida‑type solid‑lipid particles (~100‑fold) had >100‑fold higher relative bioavailability versus standard curcumin. (43)

In the U.S., a large share (55%) of the turmeric dietary supplement market is comprised of products formulated to enhance curcumin bioavailability, including proprietary products where curcuminoid extracts are often combined with some type of lipophilic carrier to increase absorption, or products combining curcumin with piperine to decrease metabolism. (46) However, as the quality of these products may vary, we would recommend the use of USP-grade supplements. Furthermore, nanoformulation-based combination therapy has emerged as a potent approach for drug delivery systems. (47) A nanodrug co-delivery system incorporating chemotherapeutic agents has demonstrated greater cancer cell sensitivity. (48, 49) Nano-curcumin preparations or formulations such as CurcuWim, Phytocurcumin and CGM which are designed to enhance absorption are therefore recommended. (50-53)

Safety and dose in everyday use

• Typical dose ranges

  • Many studies and consumer guidelines use 500–2,000 mg/day of turmeric or curcumin, often in extract form.​

  • Highly bioavailable formulations (e.g., CGM, TS‑P1) can show good effects at 150–500 mg/day of curcumin.​

• Safety

  • Acceptable daily intake is roughly up to 3 mg/kg/day of curcumin for long‑term use, though short studies used much higher doses

Practical selection tips

• Prefer:

  • A named technology with human PK/safety data (phytosome, fenugreek‑curcumin, specific micellar or solid‑lipid system).​

  • Third‑party tested brands (NSF, USP, Informed‑Choice, ConsumerLab listing) to reduce risk of contaminants like lead or microbes.​

• Use with caution or avoid:

  • High‑dose piperine combinations if taking prescription drugs, due to interaction potential.​

  • Products that do not disclose curcumin content, only “turmeric complex,” or that use proprietary blends without amounts

Table 1. Examples of bio-enhanced preparations.

Figure 2. Curcumin: Clinical evidence and summary

If you’ve found this work valuable, please consider upgrading to a paid subscription. Your support helps me continue independent research and share practical, evolving insights—while giving you access to deeper content and more direct engagement.

New Here?

Start with the: Cancer and the Metabolic Library

Medical Disclaimer: The discussion of repurposed medications and nutraceuticals in this article is intended to review the scientific literature and does not constitute a recommendation for self-treatment. Decisions regarding the use of off-label therapies should be made in consultation with a qualified healthcare professional familiar with the patient’s medical history and current treatment plan. Please see the full Medical Disclaimer on the introductory page to Marik’s Cancer & Metabolic Healing Playbook.

References

1. Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11:2376.

2. Pal S, Bhattacharyya S, Choudhuri T, Datta GK, Das T, Sa G. Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detect. Prev. 2005;29(5):470–8.

3. Mansouri K, Rasoulpoor S, Daneshkhah A, Abolfathi S, Salari N, Mohammadi M, et al. Clinical effects of curcumin in enhancing cancer therapy: A systematic review. BMC Cancer. 2020;20(1):791.

4. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett. 2008;267(1):133–64.

5. Santosa D, Suharti C, Riwanto I, Dharmana E, Pangarsa EA, Setiawan B, et al. Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial. Caspian. J Intern Med. 2022;13(2):375–84.

6. Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1b, IL-6, and TNF-a as well as cyclin E in TNF-a-treated HaCaT cells; NF-kB and MAPKs as potential upstream targets. Int. J Mol. Med. 2007;19(3):469–74.

7. Xiang DB, Zhang KQ, Zeng YL, Yan QZ, Shi Z, Tuo QH, et al. Curcumin: From a controversial “panacea” to effective antineoplastic products. Medicine (Baltimore). 2020;99(2):e18467.

8. Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza NT, Vo TT, et al. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis. 2009;30(11):1949–56.

9. Wang JY, Wang X, Wang XJ, Zheng BZ, Wang Y, Wang X, et al. Curcumin inhibits the growth via Wnt/B-catenin pathway in non-small-cell lung cancer cells. Eur Rev Med Pharmacol. Sci. 2018;22(21):7492–9.

10. Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012;21(5):407–12.

11. Ye MX, Li Y, Yin H, Zhang J. Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int. J Mol. Sci. 2012;13(3):3959–78.

12. Katta S, Srivastava A, Thangapazham RL, Rosner IL, Cullen J, Li H, et al. Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells. Int. J Mol. Sci. 2019;20(19).

13. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009;29(6):1895–9.

14. Lee JC, Kinniry PA, Arguiri E, Serota M, Kanterakis S, Chatterjee S, et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat. Res. 2010;173(5):590–601.

15. Panahi Y, Darvishi B, Ghanei M, Jowzi N, Beiraghdar F, Varnamkhasti BS. Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-kB pathway. Cytokine Growth Factor Rev. 2016;28:21–9.

16. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008;14(14):4491–9.

17. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res (Phila). 2011;4(3):354–64.

18. Li Y, Zhang T. Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett. 2014;346(2):197–205.

19. Zoi V, Galani V, Lianos GD, Voulgaris S, Kyritsis AP, Alexiou GA. The Role of Curcumin in Cancer Treatment. Biomedicines. 2021;9(9).

20. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 2006;1091:151–69.

21. Pandey A, Vishnoi K, Mahata S, Tripathi SC, Misra SP, Misra V, et al. Berberine and Curcumin Target Survivin and STAT3 in Gastric Cancer Cells and Synergize Actions of Standard Chemotherapeutic 5-Fluorouracil. Nutr. Cancer. 2015;67(8):1293–304.

22. Yim-im W, Sawatdichaikul O, Semsri S, Horata N, Mokmak W, Tongsima S, et al. Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinformatics. 2014;15(1):261.

23. Hu S, Xu Y, Meng L, Huang L, Sun H. Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther. Med. 2018;16(2):1266–72.

24. Wang K, Fan H, Chen Q, Ma G, Zhu M, Zhang X, et al. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro. Anticancer Drugs. 2015;26(1):15–24.

25. Starok M, Preira P, Vayssade M, Haupt K, Salome L, Rossi C. EGFR Inhibition by Curcumin in Cancer Cells: A Dual Mode of Action. Biomacromolecules. 2015;16(5):1634–42.

26. Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol. Med Rep. 2012;6(6):1267–70.

27. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75(8):2077–82.

28. James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015;364(2):135–41.

29. Kunnumakkara AB, Harsha C, Banik K, Vikkurthi R, Sailo BL, Bordoloi D. Is curcumin bioavailability a problem in humans: Lessons from clinical trials. Expert Opinion on Drug Metabolism & Toxicology. 2019;15:705–33.

30. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 2010;9(1):8–14.

31. Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol. Pharm Pract. 2012;18(2):186–90.

32. Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Ehtejab G. A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer. J. Cancer. Sci. Ther. 2013;5:320–4.

33. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 2011;68(1):157–64.

34. Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, et al. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology. 2016;90(2):69–78.

35. Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019;149(7):1133–9.

36. Pastorelli D, Fabricio ASC, Giovanis P, D’Ippolito S, Fiduccia P, Soldà C, et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacol. Res. 2018;132:72–9.

37. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin. Oncol. 1997;15(6):2403–13.

38. Saghatelyan T, Tananyan A, Janoyan N, Tadevosyan A, Petrosyan H, Hovhannisyan A, et al. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine. 2020;70:153218.

39. Notice to US Food and Drug Administraion of the conclusion that the intended use of curcumin is generally recognized as safe. https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory; 2018.

40. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 2006;6:10.

41. Panahi Y, Saadat A, Beiraghdar F, Nouzari SM, Jalalian HR. Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: A randomized double-blind placebo-controlled trial. Journal of Functional Foods. 2014;6:615–22.

42. Halegoua-Demarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, et al. Liver injury associated with tumeric - A growing problem: Ten cases from the drug-induced liver injury network [DILIN]. Am. J. Med. 2022.

43. Jamwal R. Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers. J Integr Med. 2018;16(6):367–74.

44. Guorgui J, Wang R, Mattheolabakis G, Mackenzie GG. Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice. Arch Biochem. Biophys. 2018;648:12–9.

45. Matthewman C, Krishnakumar IM, Swick AG. Review: bioavailability and efficacy of ‘free’ curcuminoids from curcumagalactomannoside (CGM) curcumin formulation. Nutr Res Rev. 2024;37(1):14–31.

46. Skiba MB, Luis PB, Alfafara C, Billheimer D, Schneider C, Funk JL. Curcuminoid Content and Safety-Related Markers of Quality of Turmeric Dietary Supplements Sold in an Urban Retail Marketplace in the United States. Mol. Nutr. Food Res. 2018;62(14):e1800143.

47. Desai P, Ann D, Wang J, Prabhu S. Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies. Crit Rev Ther. Drug Carrier Syst. 2019;36(1):59–91.

48. Nguyen HT, Phung CD, Thapa RK, Pham TT, Tran TH, Jeong JH, et al. Multifunctional nanoparticles as somatostatin receptor-targeting delivery system of polyaniline and methotrexate for combined chemo-photothermal therapy. Acta Biomater. 2018;68:154–67.

49. Tan BL, Norhaizan ME. Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer. Molecules. 2019;24(14).

50. Moballegh Nasery M, Abadi B, Poormoghadam D, Zarrabi A, Keyhanvar P, Tavakol S, et al. Curcumin delivery mediated by bio-based nanoparticles: A review. Molecules. 2020;25:689.

51. Valizadeh H, Danshina S, Gencer MZ, Ammari A, Sadeghi A, Aslani S. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. International Immunopharmacology. 2020;89:107088.

52. Ahmadi R, Salari S, Reihani H, Eslami S. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial. Food Science & Nutrition. 2021;9:4068–75.

53. Rahimi HR, Nedaeinia R, Shamloo AS, Nikdoust S. Novel delivery system for natural products: Nano-curcumin formulations. AJP. 2016;6:383.